close

Pharmasset, Inc., a clinical-stage pharmaceutical company, focuses on discovering, developing, and commercializing drugs to treat viral infections. Its primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV). The company has three product candidates under development, which include Clevudine, an oral, once-daily pyrimidine nucleoside analog, which is under Phase III clinical trials for the treatment of chronic HBV infection; R7128, a pro-drug of PSI-6130 has completed Phase I clinical trial for the treatment of HCV, through a collaboration with F. Hoffmann-LaRoche, Ltd. and Hoffmann-La Roche, Inc.; and Racivir, an oral, once-daily cytidine nucleoside analog, which has completed a Phase II clinical trial for the treatment of HIV. In addition, Pharmasset engages in the development of DFC, an oral, once-daily deoxycytidine nucleoside analog, for the treatment of HIV; and PSI-7851 for the treatment of HCV. It collaboration and licensing agreements with Boehringer Ingelheim Chemicals, Inc.; University of Cincinnati; Bukwang Pharm. Co., Ltd.; University of Georgia Research Foundation, Inc. and Yale University; Incyte Corporation; Emory University; and RFS Pharma LLC. The company was founded in 1998 and is based in Princeton, New Jersey.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	136.97
Volume	0
Volume Avg	(mio) 2.31
52 Week High	137.01
52 Week Low	22.64
PE	N/A
PE (group average)	N/A
EPS Year	-1.25
EPS change Q/Q	-20.29%
EPS change Q/Q Yr ago	-1.85%
EPS change Q/Q next Q est	-41.03%
EPS change Y/Y	-22.32%
REV change Q/Q	0%
REV change Q/Q Yr ago	-33.33%
EPS next Q est	-0.39
EPS next Y est	-2.11
Divident Annual	0.00
Dividend Yield	0%